Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO-B) Divestments (2020 - 2023)

Bio-Rad Laboratories (BIO-B) reported Divestments of $2.5 million for Q4 2023, up 6150.0% year-over-year from $40000.0 in Q4 2022, and up 6150.0% on a QoQ basis from $40000.0 in Q4 2022.

Bio-Rad Laboratories (BIO-B) has 3 years of Divestments data on file, last reported at $2.5 million in Q4 2023.

  • Quarterly Divestments rose 6150.0% year-over-year to $2.5 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.5 million (up 6250.0% YoY) and the FY2023 annual result came in at $2.5 million, up 78.57% from the prior year.
  • Divestments improved to $2.5 million in Q4 2023 per BIO-B's latest filing, from $40000.0 in the prior quarter.
  • Across five years, Divestments topped out at $12.2 million in Q2 2020 and bottomed at $40000.0 in Q4 2022.
  • The 3-year median for Divestments is $2.5 million (2023), against an average of $4.9 million.
  • Peak annual rise in Divestments reached 6150.0% in 2023, while the deepest fall reached 6150.0% in 2023.
  • Tracing BIO-B's Divestments over 3 years: stood at $12.2 million in 2020, then plunged by 99.67% to $40000.0 in 2022, then soared by 6150.0% to $2.5 million in 2023.
  • Per Business Quant, the three latest BIO-B Divestments figures stand at $2.5 million (Q4 2023), $40000.0 (Q4 2022), and $12.2 million (Q2 2020).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Divestments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Bio-Rad Laboratories - - 309.40 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 2.50 Mn
Dec 31, 2022 40,000.00
Jun 30, 2020 12.20 Mn